The promise of cancer immunotherapy and in particular checkpoint inhibitors that target the PD1 PDL1 signaling pathway is the topic of this episode.

We hear about the latest data presented at the 2015 annual meeting of the American Association for Cancer Research (AACR) in Philadelphia.

Interviews with Dr Julie Brahmer (Johns Hopkins), Dr Leisha Emens (at the time of recording at Johns Hopkins and now at the University of Pittsburgh) and Dr Ira Mellman (Genentech) take us on a journey that highlights some of the challenges and opportunities.

Dr Leisha Emens Johns Hopkins

Lung cancer is the leading cause of cancer death in the United States.

Dr Roy Herbst

Dr Roy Herbst at 2014 SITC annual meeting

“Personalized Immunotherapy for Non-Small Cell Lung Cancer was the title of an outstanding presentation by Roy Herbst MD PhD, at the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).

Following his talk, Dr Herbst kindly shared his thoughts on lung cancer immunotherapy, and his experience of participating in clinical trials of checkpoint inhibitors that target the PD-1 (and it’s ligand PD-L1) cell signaling pathway.